INTERCEPT is not approved for sale in the United States and certain other countries.

SIGN UP FOR OUR
E-NEWSLETTER

INTERCEPT eNews delivers product news & information updates.

INTERCEPT Platelets

Approval of the INTERCEPT Blood System for platelets in 2002 represented a significant advancement in blood safety.  For the first time, bacterial contamination risks unique to platelets due to their room temperature storage could be proactively mitigated while simultaneously providing protection from a wide variety of viruses, protozoa, and leukocytes.

platelet_ds_set

Proven in routine use The technology is in routine use in over 80 blood centers throughout Europe and the Middle East.  An extensive hemovigilence program has documented the transfusion outcomes for more than 30,000 platelet components.

Reduced transfusion reactions reported Two routine INTERCEPT users have reported detailed data comparing the rates of transfusion reactions pre and post INTERCEPT implementation.  Results from both centers indicate a significant reduction in transfusion reactions after the adoption of INTERCEPT. 1,2

Economics that make sense The INTERCEPT system is compatible with double dose platelet collections allowing blood centers to produce two therapeutic platelet units from a single INTERCEPT treatment with the dual storage set.

INTERCEPT is also approved as an alternate to gamma irradiation for the prevention of transfusion associated graft versus host disease (TA-GvHD) allowing INTERCEPT users to eliminate gamma irradiation of their platelet components while providing the greatest available protection against transfusion transmitted diseases.

Release at the same time and store up to 7 days The flexible treatment process does not impact platelet release time and is compatible with up to 7 day storage according to local requirements

Range Requirements for Processing

The INTERCEPT Blood System for platelets is compatible with a wide range of collections including platelets in additive solution, platelets in 100% plasma, single and double dose collections, as well as apheresis and whole blood collections.  Below are the processing range requirements for each of the INTERCEPT platelet processing sets.

 
Small Volume Set (SV)
Large Volume Set (LV)
Dual Storage Set (DS)
Suspension Medium*
PAS
PAS
Plasma
PAS
Plt Count
2.5-6.0x1011
2.5-7.0x1011
2.5-7.0x1011
2.5-8.0x1011**
Volume
255-325 mL
300-420 mL
255-390 mL
300-420 mL
Plasma
32 – 47%
32 – 47%
100%
32 – 47%
RBC
<4x106/mL
<4x106/mL
<4x106/mL
<4x106/mL
CAD time
4–16 hrs
6-16 hrs
16-24 hrs
6-16 hrs
Integrated Storage Containers
1
1
1
2
Approved Storage
7 days
7 days
5 days
7 days
*Platelet additive solutions (PAS) currently approved for use with INTERCEPT: InterSol, SSP+
**7.1-8x1011 requires volume of 375-420mL
1 JC Osselaer et al., Blood 2005; 106(11):129a.
2 V Witt et al., Vox Sang 2006; 91 (suppl 3):178.

Learn more about INTERCEPT Platelets:

 

Untitled Document